HALO - Halozyme Operating Sales Margin

Corporate company logo of Halozyme Corp (HALO)

The global influence of Halozyme Therapeutics (HALO) is based on Big Pharma's dependence on its subcutaneous administration patents. The current operating margin confirms the effectiveness of technology licensing and partner royalties, as well as R&D successes in oncology. The value of 56.70 captures the current state of the parameter, demonstrating the dynamics of operating profit relative to revenue.

halozyme.com (HALO): Operating Sales Margin from 07/04/2022 to 11/20/2026

Halozyme - analytical breakdowns and key metrics (HALO)

- stock quotes and analyst forecast:
- market capitalization statistics:
Fundamental valuation:Halozyme Inc., HALO
Brand item of halozyme.com

It is critical for investors to filter the risks associated with Halozyme Therapeutics (HALO) by assessing the business's ability to generate operating profit before taxes and interest amidst geopolitical barriers in reagent logistics. An analysis of the operating profit margin reveals the company's real efficiency, demonstrating the fundamental strength and resilience of the operating model to external shocks, which confirms the long-term reliability of the asset.

Competitor analysis for Halozyme Therapeutics

Operating Profitability BeiGene Ltd|Operating Profitability RVMD|Operating Sales Margin AAPG (Ascentage)|Operating Sales Margin cgoncology.com CGON|UroGen Pharma - Operating Sales Margin|Operating Profit Rate BCAX|PSNL - Operating Profitability|Profitability of Operations Erasca Oncology ERAS|delcath.com (DCTH) - Operating Profitability|Y-mAbs Therapeutics - Operating Profit Rate|AURA (Aura Biosciences Inc) - Operating Margin|Operating Return on Sales candeltx.com CADL|Operating Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operating Profit Rate|Operating Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operating Profitability|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin